<unk>  is an antineoplastic agent that is FDA approved for the treatment of palliative treatment of Generalized Hodgkin’s disease (Stages III and IV, Ann Arbor modification of Rye staging system),Lymphocytic lymphoma (nodular and diffuse, poorly and well differentiated),Histiocytic lymphoma,Mycosis fungoides (advanced stages),Advanced carcinoma of the testis,Kaposi's sarcoma,
Letterer-Siwe disease (histiocytosis X). There is a Black Box Warning for this drug as shown here.  Common adverse reactions include leukopenia,alopecia,constipation, anorexia, nausea, vomiting, abdominal pain, ileus, vesiculation of the mouth, pharyngitis, diarrhea,Hypertension, Malaise, bone pain, weakness, pain in tumor-containing tissue, dizziness, jaw pain, skin vesiculation,.
Vinblastine
Pirarubicin
Zorubicin
Epirubicin
Valrubicin
Daunorubicin
Amrubicin
Mitomycin 